Τόμος 24 (2010) – Τεύχος 2 – Άρθρο 82 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 24 (2010) – Issue 2 – Article 82 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Nitric oxide levels in the dental pulp of streptozocin induced diabetic rats
Authors Efrosyne Tsirella1, Constantinos Tomos1, Stergios Tsartsalis1, Konstantinos Kallaras2, Basile Kokkasand Maria Mironidou-Tzouveleki1

1. 1st Laboratory of Pharmacology and 2. Laboratory of Experimental Physiology, Medical School, Aristotle University, Thessaloniki, Greece

Citation Tsirella, E., Tomos, C., Tsartsalis, S., Kallaras, K., Kokkas, B. et al.: Nitric oxide levels in the dental pulp of streptozocin induced diabetic rats, Epitheorese Klin. Farmakol. Farmakokinet. 24(2): 218-220 (2010)
Publication Date 2010
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)

pharmakonpress[at]pharmakonpress[.]gr

Keywords Diabetes, dental pulp, pioglitazone, nitric oxide, streptozocin.
Other Terms Review article
Summary This study’s purpose is to determine nitric oxide (NO) concentration in the dental pulp of streptozocin induced diabetic rats and to identify whether pioglitazone administration affects NO levels in the dental pulp of normoglycaemic and diabetic rats. Wistar rats were divided into four groups: N, non-diabetic controls; NP, non-diabetic rats receiving pioglitazone (3 mg/kg); DM, streptozocin treated diabetic rats (50 mg/kg); and DM+P, diabetic rats receiving pioglitazone (3 mg/kg) for 8 weeks. Nitric oxide concentration was higher in the dental pulp of diabetic rats (527 ± 23 μM) than in control rats (177 ± 2 μM) (p < 0.001). Pioglitazone treated diabetic rats did not exhibit further increase in NO levels (542 ± 13 μM) (p = 0.315 versus DM group). Treatment with pioglitazone also did not affect NO levels in non-diabetic rats (162 ± 6 μM) (p = 0.35 versus N group). In conclusion, diabetes induced vascular changes in the dental pulp may be mediated by an increase in NO levels. Pioglitazone administration does not affect NO concentration either in normoglycaemic or in diabetic rats.
References 1. Di Nardo Di Maio F., Lohinai Z., D’Arcangelo C., Esposito De Fazio P., Speranza L., De Lutiis A., Patruno A., Grilli A., Felaco M.: Nitric oxide synthase in healthy and inflamed human dental pulp. J. Dent. Res. 83: 312-316 (2004)

2. Kubes P., Suzuki M., Granger D.N.: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci USA 88: 4651-4655 (1991)

3. Nathan C.: Nitric oxide as a secretory product of mammalian cells. FASEB J. 6: 3051-3064 (1992)

4. Lohinai Z., Szabó C.: Role of nitric oxide in physiology and pathophysiology of periodontal tissues. Med. Sci. Monit. 4: 1089-1095 (1998)

5. Lohinai Z., Balla I., Marczis J., Vass Z., Kovách A.G.: Evidence for the role of nitric oxide in the circulation of the dental pulp. J. Dent. Res. 74: 1501-1506 (1995)

6. Russell B.G.: The dental pulp in diabetes mellitus. Acta Pathol. Microbiol. Scand. 70: 319-320 (1967)

7. Bissada N.F., Sharawy A.M.: Histologic study of gingival and pulpal vascular changes in human diabetics. Egypt. Dent. J. 16: 283-296 (1970)

8. Sharma S.P.: Nitric oxide and the kidney. Indian. J. Nephrol. 14: 77-84 (2004)

9. Ishibashi M., Egashira K., Hiasa K., Inoue S., Ni W., Zhao Q., Usui M., Kitamoto S., Ichiki T., Takeshita A.: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40: 687-693 (2002)

10. Yoshimoto T., Naruse M., Nishikawa M., Naruse K., Tanabe A., Seki T., Imaki T., Demura R., Aikawa E., Demura H.: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol. 272: E989-996 (1997)

11. Davila-Esqueda M.E., Vertiz-Hernandez A.A., Martinez-Morales F.: Comparative analysis of the renoprotective effects of pentoxifylline and vitamin E on streptozotocin-induced diabetes mellitus. Ren. Fail. 27: 115-122 (2005)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2010 – ANNUAL SUBSCRIPTION 2010
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

Bookmark the permalink.

Comments are closed.